Search

Displaying results 2281 - 2290 of 5079 in total
  1. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  2. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    This drug is unique from others in this class due to its rapid onset of effects and short duration of action. … [A257153] Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.[L5074]

  3. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

  4. Drug

    Placental Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15730
    Investigational

    The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues t...

  5. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.

    Products: Nu-trihexyphenidyl
  6. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182

  7. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.

  8. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  9. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by mod...

  10. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce ...

    Mixtures: OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADET, CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADET